Efficib (sitagliptin;metformin)
- Region
- 🇪🇺 EU
- Active substance
- sitagliptin;metformin
- Company
- Merck Sharp and Dohme B.V
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus, Type 2
- CHMP opinion
- Thu 24 Apr 2008
- EU approval
- Tue 15 Jul 2008
- Application
- EMEA/H/C/000896
- ATC
- A10BD07
- Official record
- www.ema.europa.eu
Indication
For patients with type-2 diabetes mellitus: Efficib is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. Efficib is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea. Efficib is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist. Efficib is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Velmetia Authorised · Merck Sharp & Dohme B.V.
- 🇪🇺 Janumet Authorised · Merck Sharp & Dohme B.V.
- 🇪🇺 Ristfor Authorised · Merck Sharp & Dohme B.V.
- 🇪🇺 Sitagliptin / Metformin hydrochloride Accord Lapsed · Accord Healthcare S.L.U.
- 🇪🇺 Sitagliptin / Metformin hydrochloride Sun Authorised · Sun Pharmaceutical Industries Europe B.V.
Follow Efficib
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.